ProKidney Corp. (Class A) (PROK) carries a Roarable Rating of D (Sell) with 44/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 10% of 52W Range • RSI-14 at 36.4 (NEUTRAL RANGE)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
While PROK currently carries a cautious 44/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.67) and Max Pain ($1.54) forces dealer call-delta covering toward $3.26.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
ProKidney Corp. (Class A) (PROK) dropped -3.29% to $1.47, trading at 10% of its 52-week range ($1.29 – $3.1). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
On October 29, 2026, ProKidney Corp. (the "Company") entered into an Open Market Sale AgreementSM (the "Sales Agreement") with Jefferies LLC (the "Sales Agent"), pursuant to which the Company may
Citigroup analyst Yigal Nochomovitz maintains ProKidney (NASDAQ:PROK) with a Buy and lowers the price target from $10 to $8.
ProKidney (NASDAQ:PROK) said it remains on track to report top-line results from the interim analysis of its Phase III PROACT 1 study in the second quarter of 2027, following stronger-than-expected patient recruitment fo
2026-10-28. The following slide deck was published by ProKidney Corp.
WINSTON-SALEM, N.C., Oct. 22, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today anno
Seven abstracts spanning CKD translational model studies and drug product characterization provide converging evidence supporting a multifactorial mechanism of action for rilparencelOne clinical abstract presents a new p
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on PROK today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for PROK. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, ProKidney Corp. (Class A) (PROK) ranks #508 by composite RQD confidence (44/100, grade D) and #468 by equity capitalization ($444.4M). Within this direct 5-issuer industry benchmark cohort, PROK leads on earnings valuation at N/A trailing P/E, while PROK leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. PROK currently leads its immediate peer cohort in composite quantitative strength at 44/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| PROK
ACTIVE
ProKidney Corp. (Class A) | D | 44/100 | — | — | -35.0% | -3.29% | $444.4M | Benchmark Subject |
| EDIT Editas Medicine Inc. | D- | 37/100 | — | — | -35.0% | -0.68% | $450.0M | /edit-vs-prok → |
| ALLO Allogene Therapeutics Inc. | D- | 38/100 | — | — | -35.0% | -3.85% | $431.9M | /allo-vs-prok → |
| AUTL Autolus Therapeutics plc | E | 25/100 | — | -27.8% | -35.0% | -3.07% | $420.5M | /autl-vs-prok → |
| CCCC C4 Therapeutics Inc. | E | 27/100 | — | — | -35.0% | -2.80% | $406.0M | /cccc-vs-prok → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), ProKidney Corp. (Class A) (PROK) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$69.0M, operating cash flow of -$120.1M, and free cash flow of -$135.3M (+13.2% YoY). On the balance sheet, PROK closed FY2025 with $335.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$69.0M | -$120.1M | -$135.3M | $335.6M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$61.2M | -$126.4M | -$155.9M | $441.1M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$35.5M | -$90.1M | -$90.1M | — | — |
As of 2026-11-01, ProKidney Corp. (Class A) (NASDAQ: PROK) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $1.47 (-3.29% 1D, market cap $444.4M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, PROK ranks #508 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), PROK carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, EDIT (Editas Medicine Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $450.0M) and ALLO (Allogene Therapeutics Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $431.9M). Among the 5-stock peer group, PROK leads on earnings multiple (N/A) while PROK leads on capital efficiency (-35.0% ROIC).
Per PROK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001850270), ProKidney Corp. (Class A) generated $0 in revenue, -$69.0M in net income, and -$135.3M in free cash flow against $335.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
PROK last traded at $1.47 (-3.29% on volume of 821,235 shares), positioning the stock -11.98% below its 50-day simple moving average ($1.67) and -19.23% below its 200-day simple moving average ($1.82). Across its 52-week range of $1.29 to $3.10, PROK sits at the 9.9% percentile with a 14-day RSI of 36.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.29 to $1.65).
Why PROK Stock dropped -3.29% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Paper Trading Arena account.